ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "PROpel and Cilostazol to Prevent Paclitaxel Neuropathy"
Episode Synopsis
Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population.
Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?
PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
Cilostazol RCT: https://doi.org/10.1002/phar.2830
Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?
PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
Cilostazol RCT: https://doi.org/10.1002/phar.2830
Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust